Evidence map›Paper›PMID 34611868›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.

Pavlos Kotidis, Masue Marbiah, Roberto Donini, Itzcóatl A Gómez, Ioscani Jimenez Del Val, Stuart M Haslam, Karen M Polizzi, Cleo Kontoravdi

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Pavlos KotidisDepartment of Chemical Engineering, Imperial College London, London, UK.
Masue MarbiahDepartment of Chemical Engineering, Imperial College London, London, UK.
Roberto DoniniDepartment of Chemical Engineering, Imperial College London, London, UK.
Itzcóatl A GómezSchool of Chemical & Bioprocess Engineering, University College Dublin, Dublin, Ireland.
Ioscani Jimenez Del ValSchool of Chemical & Bioprocess Engineering, University College Dublin, Dublin, Ireland.
Stuart M HaslamDepartment of Life Sciences, Imperial College London, London, UK.
Karen M PolizziDepartment of Chemical Engineering, Imperial College London, London, UK.
Cleo KontoravdiDepartment of Chemical Engineering, Imperial College London, London, UK. cleo.kontoravdi@imperial.ac.uk.
Imperial College London · GBUniversity College Dublin · IE

Funding

Biotechnology and Biological Sciences Research Council BB/S006206/1
6 · The paper itself

Abstract

The impact of the glycan distribution on the in vivo function and half-life of monoclonal antibodies has long motivated the genetic engineering of producer cells to achieve structures that enhance efficacy, safety and stability. To facilitate glycoengineering of IgG-producing Chinese hamster ovary cells, we present a rapid protocol that involves the use of RNA interference for the knockdown of genes of interest coupled with capillary gel electrophoresis and laser-induced fluorescence detection (CGE-LIF) for fast, high-throughput glycan analysis. We apply this methodology to the Fut8 gene, responsible for the addition of core fucose, which is a typical target for increasing antibody-dependent cellular cytotoxicity.

Indexed as

GlycomicsAnimalsAntibodies, MonoclonalCHO CellsCricetinaeCricetulusElectrophoresis, CapillaryPolysaccharidesRNA InterferenceAntibodies, MonoclonalPolysaccharidesAntibody-dependent cell cytotoxicityCapillary gel electrophoresisChinese hamster ovary cellsFucosylationGene knockdownRNAisiRNA

Identifiers

PMID34611868
OpenAlexW3203310489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.